- Veterinarian Survey 2020
- What is compounding?
- Facts About FDA's Guidance for Industry #256
- Why Compounding Pharmacies Use Bulk Active Pharmaceutical Ingredients
- Why Compounding from Finished Goods Will Increase Costs
- The Case for Office Use of Compounded Medications
- Anticipatory Compounding: An Important Part of Pharmacy Practice
- Pharmacy or Manufacturer? Size Doesn't Matter.
- The Negatives About FDA’s “Positive List.”
- The Law
In response to requests to extend the comment period for the revised draft guidance, “Compounding Animal Drugs from Bulk Drug Substances,” the FDA plans to provide an additional 120 days for the public to submit comments. The initial comment period is scheduled to end on February 18, 2020, but FDA will be reopening the comment period using the same docket number. Otherwise, the submission process remains unchanged.
The new deadline to receive comments will be June 17, 2020.
A majority of the U.S. House of Representatives has co-sponsored the Horseracing Integrity Act of 2019 (HIA).
The legislation now exceeds 218 co-sponsors, which is a majority of the 435 voting members of the House. The bill was introduced in the House by Reps. Paul Tonko (D-NY) and Andy Barr (R-KY).
ALEXANDRIA, Va. (June 21, 2017) National Community Pharmacists Association (NCPA) CEO B. Douglas Hoey, RPh, MBA, issued the following statement today in support of new compounding legislation, H.R. 2871, The Preserving Patient Access to Compounded Medications Act of 2017, introduced by Reps. Morgan Griffith (R-Va.) and Henry Cuellar (D-Texas), that will improve patient access to compounded medications:
WASHINGTON – June 13, 2017 - The International Academy of Compounding Pharmacists (IACP) strongly supports new legislation, introduced by U.S. Congressmen Morgan Griffith (VA) and Henry Cuellar (TX), HR 2871 – The Preserving Patient Access to Compounded Medications Act of 2017, formally introduced on June 12, 2017. More than 300 compounding pharmacists traveled to Washington, D.C. on behalf of their patients and physicians to meet with their respective congressional representatives to discuss the Bill’s content, and to urge them to co-sponsor HR 2871.